TrialJAMA oncology2018

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.

Baohui Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.